Pharmacotoxicology of High-Dose Thiotepa
Thiotepa is an alkylating agent that was first synthesised in the 1950s. It can be administered intravenously, intravesically and intrathecally. At conventional doses the main adverse effect is haematopoietic toxicity. For about 10 years now thiotepa has been used at high doses prior to bone marrow transplantation. High-dose thiotepa has been particularly developed in the USA, while high-dose melphalan is preferred in Europe.
KeywordsBone Marrow Transplantation Conventional Dose Autologous Bone Marrow Transplantation Main Adverse Effect Bone Marrow Rescue
Unable to display preview. Download preview PDF.
- 3.Egorin MJ, Snyder SW, Pan S, Daly C: Cellular transport and accumulation of thiotepa. Semin Oncol 1990 17 suppl 3: 7–17Google Scholar
- 5.Heidemann RL, Cole DE, Balis F: Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989 49: 736–741Google Scholar
- 11.Teicher BA, Holden SA, Eder JP, Herman S, Antman K, Frei Ill E: Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol 1990 17 suppl 3: 18–32Google Scholar
- 12.Wolff SN, Herzig RH, Fay JW: High-dose N,N’,N“triethylenethiophosphoramide thiotepa with autologous bone marrow transplantation: phase I studies. Sem Oncol 1990 17 suppl 3: 2–6Google Scholar